Garry L Jennings

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6159552/publications.pdf

Version: 2024-02-01

236 papers	12,982 citations	23567 58 h-index	25787 108 g-index
240 all docs	240 docs citations	240 times ranked	11523 citing authors

#	Article	IF	Citations
1	Uncontrolled blood pressure in Australia: a call to action. Medical Journal of Australia, 2022, 216, 61-63.	1.7	11
2	Measurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder. Frontiers in Psychiatry, 2022, 13, .	2.6	2
3	Translation and Impact of Funded Australian Cardiovascular Research: A Review With Perspective. Heart Lung and Circulation, 2021, 30, 1442-1448.	0.4	1
4	The adrenal medulla in cardiovascular medicine: an untold story. Journal of Hypertension, 2021, 39, 819-829.	0.5	6
5	The Baker Biobank: Understanding Cardiovascular Outcomes. Heart Lung and Circulation, 2020, 29, 1071-1077.	0.4	3
6	Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor. Heart Lung and Circulation, 2020, 29, 662-667.	0.4	17
7	Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension. Journal of Hypertension, 2020, 38, 1488-1495.	0.5	33
8	Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet, The, 2019, 394, 639-651.	13.7	325
9	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. Hypertension, 2019, 74, 1216-1225.	2.7	2
10	Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality. Journal of the American Heart Association, 2019, 8, e012630.	3.7	8
11	Paroxysmal Hypertension Associated With Presyncope. Hypertension, 2019, 74, 718-725.	2.7	6
12	Sex-Specific Lifestyle and Biomedical Risk Factors for Chronic Disease among Early-Middle, Middle and Older Aged Australian Adults. International Journal of Environmental Research and Public Health, 2019, 16, 224.	2.6	8
13	Y Chromosome, Hypertension and Cardiovascular Disease: Is Inflammation the Answer?. International Journal of Molecular Sciences, 2019, 20, 2892.	4.1	19
14	HDL Phospholipids, but Not Cholesterol Distinguish Acute Coronary Syndrome From Stable Coronary Artery Disease. Journal of the American Heart Association, 2019, 8, e011792.	3.7	35
15	Drug-Resistant Hypertension. Hypertension, 2019, 73, 920-925.	2.7	3
16	The Australian Cardiovascular Allianceâ€“Towards an Integrated Whole-of-Nation Strategy to Address Our Major Health Burden. Heart Lung and Circulation, 2019, 28, 198-203.	0.4	9
17	Physical activity recommendations for avoiding hypertension and its complications. Journal of Hypertension, 2019, 37, 1594-1595.	0.5	1
18	Effects of highâ€•and lowâ€•dose aspirin on adaptive immunity and hypertension in the strokeâ€prone spontaneously hypertensive rat. FASEB Journal, 2019, 33, 1510-1521.	0.5	8

#	Article	IF	Citations
19	Between-meal sucrose-sweetened beverage consumption impairs glycaemia and lipid metabolism during prolonged sitting: AÂrandomized controlled trial. Clinical Nutrition, 2019, 38, 1536-1543.	5.0	8
20	Unifocal and Multifocal Fibromuscular Dysplasia. Hypertension, 2019, 73, 7-12.	2.7	5
21	Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study. Journal of Clinical Lipidology, 2019, 13, 148-155.	1.5	2
22	Who might benefit from Systolic Blood Pressure Intervention Trial's lower blood pressure targets? LIFE in the fast lane. Journal of Hypertension, 2018, 36, 771-772.	0.5	0
23	Standing up to the cardiometabolic consequences of hematological cancers. Blood Reviews, 2018, 32, 349-360.	5.7	5
24	Blood Pressure Down Under, but Down Under What?. Hypertension, 2018, 71, 972-975.	2.7	9
25	Visit-to-visit (long-term) and ambulatory (short-term) blood pressure variability to predict mortality in an elderly hypertensive population. Journal of Hypertension, 2018, 36, 1059-1067.	0.5	29
26	Yâ€¢chromosome lineage determines cardiovascular organ Tâ€¢cell infiltration in the strokeâ€prone spontaneously hypertensive rat. FASEB Journal, 2018, 32, 2747-2756.	0.5	4
27	Defining Hypertension â€" A Storm Across the Pacific. Heart Lung and Circulation, 2018, 27, 531-532.	0.4	0
28	Vascular dysfunction in the stroke-prone spontaneously hypertensive rat is dependent on constrictor prostanoid activity and Y chromosome lineage. Clinical Science, 2018, 132, 131-143.	4.3	4
29	Pioneering Australiaâ€™s First Atrial Fibrillation Guidelines. Heart Lung and Circulation, 2018, 27, 1391-1393.	0.4	0
30	How to Manage Heart Failure: New Guidelines 2018. Heart Lung and Circulation, 2018, 27, 1267-1269.	0.4	0
31	Sex-Specific Associations in Nutrition and Activity-Related Risk Factors for Chronic Disease: Australian Evidence from Childhood to Emerging Adulthood. International Journal of Environmental Research and Public Health, 2018, 15, 214.	2.6	9
32	Relation of Alcohol Consumption to Risk of Heart Failure in Patients Aged 65 to 84 Years With Hypertension. American Journal of Cardiology, 2018, 122, 1352-1358.	1.6	2
33	Hypertension and Its Complications in a Young Man With Autoimmune Disease. Hypertension, 2017, 69, 536-544.	2.7	1
34	Case of Refractory Hypertension Controlled by Repeated Renal Denervation and Celiac Plexus Block. Hypertension, 2017, 69, 978-984.	2.7	4
35	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension, 2017, 69, 985-991.	2.7	3
36	Case of Chronic Indolent Pheochromocytoma That Caused Medically Controlled Hypertension but Treatment-Resistant Diabetes Mellitus. Hypertension, 2017, 69, 740-746.	2.7	3

#	Article	IF	Citations
37	Pet ownership and survival in the elderly hypertensive population. Journal of Hypertension, 2017, 35, 769-775.	0.5	50
38	Antihypertensive therapy. Journal of Hypertension, 2017, 35, 1778-1779.	0.5	0
39	Prediction of 10-year Risk of Incident Heart Failure in Elderly Hypertensive Population: The ANBP2 Study. American Journal of Hypertension, 2017, 30, 88-94.	2.0	6
40	Australian adults' behaviours, knowledge and perceptions of risk factors for heart disease: A cross-sectional study. Preventive Medicine Reports, 2017, 8, 204-209.	1.8	13
41	Sugar- and Intense-Sweetened Drinks in Australia: A Systematic Review on Cardiometabolic Risk. Nutrients, 2017, 9, 1075.	4.1	16
42	Exploring Motivation and Barriers to Physical Activity among Active and Inactive Australian Adults. Sports, 2017, 5, 47.	1.7	125
43	Fasting Plasma Glucose, Self-Appraised Diet Quality and Depressive Symptoms: A US-Representative Cross-Sectional Study. Nutrients, 2017, 9, 1330.	4.1	4
44	A warning against heart disease complacency in 2016. Medical Journal of Australia, 2016, 204, 172-172.	1.7	0
45	Reflections on the Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Acute Coronary Syndromes Guideline 2016 â€“ A New International Benchmark. Heart Lung and Circulation, 2016, 25, 1048-1050.	0.4	1
46	Impact of nurse-mediated management on achieving blood pressure goal levels in primary care: Insights from the Valsartan Intensified Primary carE Reduction of Blood Pressure Study. European Journal of Cardiovascular Nursing, 2016, 15, 409-416.	0.9	8
47	Predictive Performance of Echocardiographic Parameters for Cardiovascular Events Among Elderly Treated Hypertensive Patients. American Journal of Hypertension, 2016, 29, 821-831.	2.0	10
48	Compound 21, a selective agonist of angiotensin AT₂ receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. British Journal of Pharmacology, 2016, 173, 729-740.	5.4	51
49	Hypertensive Encephalopathy and Renal Failure in a Young Man. Hypertension, 2016, 67, 6-13.	2.7	3
50	A Woman With Treatment-Resistant Hypertension. Hypertension, 2016, 67, 243-250.	2.7	2
51	Impact of a nurseâ€led home and clinicâ€based secondary prevention programme to prevent progressive cardiac dysfunction in highâ€risk individuals: the Nurseâ€led Intervention for Less Chronic Heart Failure (<scp>NILâ€CHF</scp>) randomized controlled study. European Journal of Heart Failure, 2015, 17, 620-630.	7.1	33
52	Essential Service Standards for Equitable National Cardiovascular Care for Aboriginal and Torres Strait Islander People. Heart Lung and Circulation, 2015, 24, 126-141.	0.4	21
53	A Strategy for Translating Evidence Into Policy and Practice to Close the Gap - Developing Essential Service Standards for Aboriginal and Torres Strait Islander Cardiovascular Care. Heart Lung and Circulation, 2015, 24, 119-125.	0.4	9
54	Response to Letter to the Editor: Essential Service Standards for Equitable National Cardiovascular Care for Aboriginal and Torres Strait Islander people. Heart Lung and Circulation, 2015, 24, 627.	0.4	0

#	Article	IF	Citations
55	A New Guideline on Treatment of Hypertension in Those with Coronary Artery Disease. Heart Lung and Circulation, 2015, 24, 1037-1040.	0.4	8
56	Prevalence and treatment of familial hypercholesterolaemia in Australian communities. International Journal of Cardiology, 2015, 185, 69-71.	1.7	66
57	Rare Cause of Severe Hypertension in a Young Woman. Hypertension, 2015, 65, 21-24.	2.7	1
58	Predictors of Mean Arterial Pressure Morning Rate of Rise and Power Function in Subjects Undergoing Ambulatory Blood Pressure Recording. PLoS ONE, 2014, 9, e93186.	2.5	9
59	An Unusual Cause of Mineralocorticoid Hypertension. Hypertension, 2014, 64, 689-692.	2.7	3
60	Exercise and Dietary Influences on Arterial Stiffness in Cardiometabolic Disease. Hypertension, 2014, 63, 888-893.	2.7	39
61	Origin of the Y Chromosome Influences Intrarenal Vascular Responsiveness to Angiotensin I and Angiotensin (1-7) in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension, 2014, 64, 1376-1383.	2.7	9
62	Renovascular Hypertension. Hypertension, 2014, 64, 1165-1168.	2.7	3
63	More rigorous protocol adherence to intensive structured management improves blood pressure control in primary care. Journal of Hypertension, 2014, 32, 1342-1350.	0.5	10
64	ABCA12 Regulates ABCA1-Dependent Cholesterol Efflux from Macrophages and the Development of Atherosclerosis. Cell Metabolism, 2013, 18, 225-238.	16.2	46
65	Hypertension Guidelines. Hypertension, 2013, 62, 660-665.	2.7	21
66	Recent Clinical Trials of Hypertension Management. Hypertension, 2013, 62, 3-7.	2.7	12
67	Determinants of Achieving Early Blood Pressure Control with Monotherapy in a Primary Care Setting. Journal of Clinical Hypertension, 2013, 15, 674-680.	2.0	3
68	Pressure points in primary care. Journal of Hypertension, 2013, 31, 1265-1271.	0.5	18
69	Integrated health research centres for Australia. Medical Journal of Australia, 2013, 199, 320-321.	1.7	6
70	Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ, The, 2012, 345, e7156-e7156.	6.0	33
71	Y Are Males So Difficult to Understand?. Hypertension, 2012, 59, 525-531.	2.7	19
72	20 APSH PRESIDENT'S LECTURE. Journal of Hypertension, 2012, 30, e6-e7.	0.5	0

#	Article	IF	Citations
73	Assessing cardiovascular risk in regional areas: the Healthy Hearts â€“ Beyond City Limits program. BMC Health Services Research, 2012, 12, 296.	2.2	10
74	Hypertension and Diabetes in Indigenous Communities. Heart Lung and Circulation, 2012, 21, 648.	0.4	0
75	Hypertension and Diabetes in Indigenous Communities. Heart Lung and Circulation, 2011, 20, S1.	0.4	0
76	Optimising management of hypertension in primary care: The Valsartan Intensified Primary Care Reduction of Blood Pressure (Viper-Bp) Study. International Journal of Cardiology, 2011, 153, 317-322.	1.7	11
77	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	1.6	156
78	Plasma Lipidomic Analysis of Stable and Unstable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2723-2732.	2.4	265
79	Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk. Heart, 2011, 97, 1766-1770.	2.9	31
80	Blood pressure up in a puff of smoke. Journal of Hypertension, 2010, 28, 1806-1808.	0.5	2
81	Hypertension and adherence to physical activity programs--a sticky matter!. British Journal of Sports Medicine, 2010, 44, 994-997.	6.7	6
82	Obesity and left ventricular hypertrophy: does my heart look big on this?. Journal of Hypertension, 2010, 28, 2190-2193.	0.5	7
83	Pattern of blood pressure in Australian adults: Results from a National Blood Pressure Screening Day of 13,825 adults. International Journal of Cardiology, 2010, 145, 461-467.	1.7	34
84	Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. Circulation, 2010, 121, 1439-1446.	1.6	172
85	A Novel Measure of the Power of the Morning Blood Pressure Surge From Ambulatory Blood Pressure Recordings. American Journal of Hypertension, 2010, 23, 1074-1081.	2.0	33
86	Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention. Journal of Clinical Nursing, 2009, 18, 678-686.	3.0	5
87	Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and) Tj ETQq1 1 0.784314 rgBT /Ove lo 2009, 104, 1484-1489.	1.6	46
88	The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clinical Research in Cardiology, 2009, 98, 421-433.	3.3	11
89	Compliance mismatch between stenotic and distal reference segment is associated with coronary artery disease instability. Atherosclerosis, 2009, 206, 179-185.	0.8	9
90	Reduced Phosphoinositide 3-Kinase (p110Î±) Activation Increases the Susceptibility to Atrial Fibrillation. American Journal of Pathology, 2009, 175, 998-1009.	3.8	151

#	Article	IF	Citations
91	Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation, 2009, 120, 1380-1389.	1.6	103
92	Human Sympathetic Nerve Biology. Annals of the New York Academy of Sciences, 2008, 1148, 338-348.	3.8	84
93	PROMOTING PHYSIOLOGICAL HYPERTROPHY IN THE FAILING HEART. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 438-441.	1.9	7
94	CHRONIC MENTAL STRESS IS A CAUSE OF ESSENTIAL HYPERTENSION: PRESENCE OF BIOLOGICAL MARKERS OF STRESS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 498-502.	1.9	134
95	Cardiovascular Risk Factors Over 20 Years: The Baker Heart Risk Clinic. Heart Lung and Circulation, 2008, 17, S208-S209.	0.4	0
96	Altered Sympathetic Nervous Reactivity and Norepinephrine Transporter Expression in Patients With Postural Tachycardia Syndrome. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 103-109.	4.8	79
97	Smaller Aortic Dimensions Do Not Fully Account for the Greater Pulse Pressure in Elderly Female Hypertensives. Hypertension, 2008, 51, 1129-1134.	2.7	34
98	Protective effects of exercise and phosphoinositide 3-kinase(p110Â) signaling in dilated and hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 612-617.	7.1	269
99	Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: Reduction by a selective serotonin reuptake inhibitor. Stress, 2007, 10, 295-304.	1.8	48
100	Similar Effects of Treatment on Central and Brachial Blood Pressures in Older Hypertensive Subjects in the Second Australian National Blood Pressure Trial. Hypertension, 2007, 49, 1242-1247.	2.7	59
101	Response to Effects of Angiotensin-Converting Enzyme Inhibitors on Central Blood Pressure. Hypertension, 2007, 50, .	2.7	0
102	Left ventricular hypertrophy: beyond the image and defining the human cardiac phenotype in hypertension. Journal of Hypertension, 2007, 25, 941-947.	0.5	8
103	Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease. Cardiovascular Research, 2007, 75, 813-820.	3.8	36
104	DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILURE. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 255-262.	1.9	298
105	Rate of Morning Increase in Blood Pressure Is Elevated in Hypertensives. American Journal of Hypertension, 2006, 19, 1010-1017.	2.0	26
106	Response to Brachial and Central Arterial Pressure. Hypertension, 2006, 48, .	2.7	0
107	Inhibition of Fibroblast Growth Factor Receptor Signaling Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1845-1851.	2.4	43
108	Brachial Blood Pressure But Not Carotid Arterial Waveforms Predict Cardiovascular Events in Elderly Female Hypertensives. Hypertension, 2006, 47, 785-790.	2.7	174

#	Article	IF	Citations
109	The neuronal noradrenaline transporter, anxiety and cardiovascular disease. Journal of Psychopharmacology, 2006, 20, 60-66.	4.0	73
110	Arterial pulse waveforms: defined at birth or barking up the wrong arterial tree?. Journal of Hypertension, 2005, 23, 1337-1339.	0.5	0
111	Finding improved medicines: the role of academicâ€“industrial collaboration. Nature Reviews Drug Discovery, 2005, 4, 891-897.	46.4	40
112	Who's really hypertensive? â€“ Quality control issues in the assessment of blood pressure for randomized trials. Blood Pressure, 2005, 14, 133-138.	1.5	11
113	Predictors of Failure to Initiate Randomized Treatment in a Large Trial of Antihypertensive Drug Therapy in the Aged. American Journal of Hypertension, 2005, 18, 885-888.	2.0	1
114	Proliferation of Neointimal Smooth Muscle Cells after Arterial Injury. Journal of Biological Chemistry, 2004, 279, 42221-42229.	3.4	36
115	Large Artery Stiffness Is Not Related to Plasma Cholesterol in Older Subjects with Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 962-968.	2.4	41
116	The left atrium in hypertension. Journal of Hypertension, 2004, 22, 1473-1474.	0.5	4
117	Large-Artery Stiffness Contributes to the Greater Prevalence of Systolic Hypertension in Elderly Women. Journal of the American Geriatrics Society, 2004, 52, 368-373.	2.6	64
118	Serotonin blockade protects against early microvascular constriction following atherosclerotic plaque rupture. European Journal of Pharmacology, 2004, 486, 85-89.	3.5	6
119	Cardiac Sympathetic Nerve Biology and Brain Monoamine Turnover in Panic Disorder. Annals of the New York Academy of Sciences, 2004, 1018, 505-514.	3.8	56
120	Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery disease. American Heart Journal, 2004, 148, 341-347.	2.7	21
121	Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. Journal of Hypertension, 2004, 22, 1529-1534.	0.5	32
122	Measuring arterial function in diabetes. Journal of Hypertension, 2004, 22, 1863-1865.	0.5	9
123	Relation of local platelet glycoprotein IIb/IIIa independent activation during coronary angioplasty in acute myocardial infarction to recovery of left ventricular function. American Journal of Cardiology, 2003, 92, 446-450.	1.6	0
124	A Comparison of Outcomes with Angiotensin-Convertingâ€“Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. New England Journal of Medicine, 2003, 348, 583-592.	27.0	1,078
125	Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-Î³ Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation. Circulation, 2003, 107, 2548-2550.	1.6	94
126	Sex Hormones and Cardiomyopathic Phenotype Induced by Cardiac Î²2-Adrenergic Receptor Overexpression. Endocrinology, 2003, 144, 4097-4105.	2.8	73

#	Article	IF	Citations
127	??-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics and Genomics, 2003, 13, 379-382.	5.7	137
128	Increased Suicide Rate in the Middle-Aged and Its Association With Hours of Sunlight. American Journal of Psychiatry, 2003, 160, 793-795.	7.2	93
129	The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R909-R916.	1.8	95
130	Experimental Rupture of Atherosclerotic Lesions Increases Distal Vascular Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 153-160.	2.4	29
131	Tranilast Prevents Activation of Transforming Growth Factor-Î² System, Leukocyte Accumulation, and Neointimal Growth in Porcine Coronary Arteries After Stenting. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 940-948.	2.4	54
132	Left ventricular remodelling impacts on coronary flow reserve in hypertensive patients: is there a vascular mechanism?. Journal of Hypertension, 2002, 20, 1291-1293.	0.5	10
133	Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. Journal of the American College of Cardiology, 2002, 39, 1020-1025.	2.8	290
134	Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clinical Endocrinology, 2002, 56, 745-753.	2.4	13
135	Mechanical strain stimulates a mitogenic response in coronary vascular smooth muscle cells via release of basic fibroblast growth factor. American Journal of Hypertension, 2001, 14, 1128-1134.	2.0	25
136	Gender differences in the timing of arterial wave reflection beyond differences in body height. Journal of Hypertension, 2001, 19, 2197-2203.	0.5	153
137	Sympathetic Nerve Biology In Essential Hypertension. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 986-989.	1.9	119
138	Large Artery Stiffness: Structural And Genetic Aspects. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1040-1043.	1.9	40
139	Low Blood Flow After Angioplasty Augments Mechanisms of Restenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 208-213.	2.4	52
140	Mechanisms of Carvedilol Action in Human Congestive Heart Failure. Hypertension, 2001, 37, 1216-1221.	2.7	19
141	Supplemental oxygen does not modulate responses to acetylcholine or ascorbic acid in the forearm of patients with congestive heart failure. Clinical Science, 2000, 99, 57-63.	4.3	5
142	Supplemental oxygen does not modulate responses to acetylcholine or ascorbic acid in the forearm of patients with congestive heart failure. Clinical Science, 2000, 99, 57.	4.3	2
143	Phenotypic Evidence of Faulty Neuronal Norepinephrine Reuptake in Essential Hypertension. Hypertension, 2000, 36, 824-829.	2.7	88
144	The â€˜adrenaline hypothesisâ€™ of hypertension revisited. Journal of Hypertension, 2000, 18, 717-723.	0.5	67

#	Article	IF	Citations
145	Kinins in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R897-R904.	1.8	52
146	Preserved ventricular contractility in infarcted mouse heart overexpressing Î²₂-adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H2456-H2463.	3.2	31
147	Response to balloon injury is vascular bed specificA consequence of de novo vessel structure?. Atherosclerosis, 2000, 151, 407-414.	0.8	20
148	Transient Improvement of Acetylcholine Responses After Short-Term Oral L-Arginine in Forearms of Human Heart Failure. Journal of Cardiovascular Pharmacology, 2000, 36, 31-37.	1.9	10
149	LEFT VENTRICULAR MASS AND MICROALBUMINURIA: RELATION TO AMBULATORY BLOOD PRESSURE. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 514-516.	1.9	17
150	Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Journal of the American College of Cardiology, 1999, 33, 1553-1559.	2.8	34
151	Human obesity is associated with a chronic elevation in brain 5-hydroxytryptamine turnover. Clinical Science, 1999, 96, 191-197.	4.3	24
152	Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. Journal of Hypertension, 1999, 17, 413-418.	0.5	66
153	Neural mechanisms in human obesity-related hypertension. Journal of Hypertension, 1999, 17, 1125-1133.	0.5	314
154	Immune response to a single bout of exercise in young and elderly subjects. Mechanisms of Ageing and Development, 1998, 100, 121-132.	4.6	30
155	Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet, The, 1998, 351, 879.	13.7	65
156	The failing human heart does not release nitrogen oxides. Life Sciences, 1998, 62, 883-887.	4.3	11
157	Vascular types I and II transforming growth factor-beta receptor expression: differential dependency on tyrosine kinases during induction by TGF-Î². FEBS Letters, 1998, 422, 197-200.	2.8	8
158	Differential Effect of Acute Baroreceptor Unloading on Cardiac and Systemic Sympathetic Tone in Congestive Heart Failure. Journal of the American College of Cardiology, 1998, 31, 583-587.	2.8	59
159	Inhibitory effects of tranilast on expression of transforming growth factor-Î² isoforms and receptors in injured arteries. Atherosclerosis, 1998, 137, 267-275.	0.8	63
160	Sympathetic Activity in Patients With Panic Disorder at Rest, Under Laboratory Mental Stress, and During Panic Attacks. Archives of General Psychiatry, 1998, 55, 511.	12.3	194
161	Assessment of prevalence of left ventricular hypertrophy in hypertension. Journal of Hypertension, 1998, 16, 715-723.	0.5	46
162	The effects of voluntary running on cardiac mass and aortic compliance in Wistarâ€“Kyoto and spontaneously hypertensive rats. Journal of Hypertension, 1998, 16, 181-185.	0.5	35

#	Article	IF	Citations
163	Human Muscle Sympathetic Activity and Cardiac Catecholamine Spillover: No Support for Augmented Sympathetic Noradrenaline Release by Adrenaline Co-Transmission. Clinical Science, 1998, 94, 383-393.	4.3	14
164	Panic disorder: coronary spasm as a basis for cardiac risk?. Medical Journal of Australia, 1998, 168, 390-392.	1.7	63
165	Reduced Systemic Arterial Compliance Is Associated with Left Ventricular Hypertrophy and Diastolic Dysfunction in Older People. Journal of the American Geriatrics Society, 1997, 45, 803-808.	2.6	43
166	Risk factors for coronary heart disease in a population with a high prevalence of obesity and diabetes: a case-control study of the Polynesian population of Western Samoa. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 173-178.	1.5	12
167	Spontaneous running increases aortic compliance in Wistar-Kyoto rats. Cardiovascular Research, 1997, 35, 132-137.	3.8	65
168	Hormonal Therapy Increases Arterial Compliance in Postmenopausal Women. Journal of the American College of Cardiology, 1997, 30, 350-356.	2.8	252
169	Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects. Journal of the Autonomic Nervous System, 1997, 64, 57-64.	1.9	31
170	Inhibition of Protein Tyrosine Kinases Attenuates Increases in Expression of Transforming Growth Factor-Î² Isoforms and Their Receptors Following Arterial Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2461-2470.	2.4	53
171	Adrenergic Nervous System in Heart Failure. American Journal of Cardiology, 1997, 80, 7L-14L.	1.6	209
172	Regional Sympathetic Nervous Activity and Oxygen Consumption in Obese Normotensive Human Subjects. Circulation, 1997, 96, 3423-3429.	1.6	311
173	Angiotensin-Converting Enzyme Inhibition Abolishes Medial Smooth Muscle PDGF-AB Biosynthesis and Attenuates Cell Proliferation in Injured Carotid Arteries. Circulation, 1997, 96, 1631-1640.	1.6	36
174	Region-Specific Neuropeptide Y Overflows at Rest and During Sympathetic Activation in Humans. Hypertension, 1997, 29, 137-143.	2.7	85
175	Estrogen Supplementation Decreases Norepinephrine-Induced Vasoconstriction and Total Body Norepinephrine Spillover in Perimenopausal Women. Hypertension, 1997, 30, 1538-1543.	2.7	119
176	Dietary supplementation with l-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. Journal of the American College of Cardiology, 1996, 27, 1207-1213.	2.8	64
177	Oxygen consumption in the heart, hepatomesenteric bed, and brain in young and elderly human subjects, and accompanying sympathetic nervous activity. Metabolism: Clinical and Experimental, 1996, 45, 1487-1492.	3.4	10
178	LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers. Atherosclerosis, 1996, 126, 277-287.	0.8	25
179	Systemic arterial compliance is decreased in newly-diagnosed patients with coronary heart disease: implications for prediction of risk. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 495-500.	1.5	39
180	Effects of In Vivo and In Vitro L-Arginine Supplementation on Healthy Human Vessels. Journal of Cardiovascular Pharmacology, 1996, 28, 158-166.	1.9	71

#	Article	IF	Citations
181	Estrogen Enhances Basal Nitric Oxide Release in the Forearm Vasculature in Perimenopausal Women. Hypertension, 1996, 28, 330-334.	2.7	146
182	The relationship between arterial compliance, age, blood pressure and serum lipid levels. Journal of Hypertension, 1995, 13, 1718???1723.	0.5	52
183	Regional Sympathetic Nervous Activation after a Large Meal in Humans. Clinical Science, 1995, 89, 145-154.	4.3	91
184	Postprandial Sympatho-Adrenal Activity: Its Relation to Metabolic and Cardiovascular Events and to Changes in Meal Frequency. Clinical Science, 1995, 89, 349-357.	4.3	49
185	MECHANISMS FOR REDUCTION OF CARDIOVASCULAR RISK BY REGULAR EXERCISE. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 209-211.	1.9	18
186	Regional origins of 3-methoxy-4-hydroxyphenylglycol in plasma: effects of chronic sympathetic nervous activation and denervation, and acute reflex sympathetic stimulation. Journal of the Autonomic Nervous System, 1995, 55, 169-178.	1.9	29
187	Total norepinephrine spillover, muscle sympathetic nerve activity and heart-rate spectra analysis in a patient with dopamine Î²-hydroxylase deficiency. Journal of the Autonomic Nervous System, 1995, 55, 198-206.	1.9	38
188	Fallibility of plasma noradrenaline measurements in studying postprandial sympathetic nervous responses. Journal of the Autonomic Nervous System, 1995, 56, 97-104.	1.9	23
189	Central Nervous System Norepinephrine Turnover in Essential Hypertension. Annals of the New York Academy of Sciences, 1995, 763, 679-694.	3.8	11
190	Adverse consequences of high sympathetic nervous activity in the failing human heart. Journal of the American College of Cardiology, 1995, 26, 1257-1263.	2.8	614
191	Central nervous system noradrenergic and dopaminergic turnover in response to acute neuroleptic challenge. Life Sciences, 1995, 56, 1545-1555.	4.3	7
192	Effects of Aging on the Responsiveness of the Human Cardiac Sympathetic Nerves to Stressors. Circulation, 1995, 91, 351-358.	1.6	151
193	Increased Central Nervous System Monoamine Neurotransmitter Turnover and Its Association With Sympathetic Nervous Activity in Treated Heart Failure Patients. Circulation, 1995, 92, 1813-1818.	1.6	70
194	Mineralocorticoid Induced Hypertension and Noradrenaline Spillover In Man. Clinical and Experimental Hypertension, 1994, 16, 147-161.	1.3	13
195	Monoaminergic Neuronal Activity in Subcortical Brain Regions in Essential Hypertension. Blood Pressure, 1994, 3, 55-66.	1.5	31
196	EVIDENCE FOR IMPAIRED ENDOTHELIUM DEPENDENT VASODILATION IN EXPERIMENTAL LEFT VENTRICULAR DYSFUNCTION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 709-719.	1.9	14
197	Measurement of human sympathetic nervous responses to stressors by microneurography. Journal of the Autonomic Nervous System, 1994, 49, 277-281.	1.9	24
198	Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. Journal of the American College of Cardiology, 1994, 23, 570-578.	2.8	274

#	Article	IF	Citations
199	Effects of dietary marine oil supplementation on reactivity of human buttock subcutaneous arteries and forearm veins in vitro. British Journal of Pharmacology, 1994, 112, 566-570.	5.4	11
200	Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. Journal of Hypertension, 1994, 12, 291???302.	0.5	49
201	Prescribing Medication Versus Promoting Behavioural Change: A Trial of the Use of Lifestyle Management to Replace Drug Treatment of Hypertension in General Practice. Behaviour Change, 1994, 11, 177-185.	1.3	5
202	Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. Journal of Hypertension, 1993, 11, 1217???1228.	0.5	103
203	Exercise training reduces the sympathetic component of the blood pressure-heart rate baroreflex in man. Clinical Science, 1992, 82, 357-362.	4.3	57
204	Pet ownership and risk factors for cardiovascular disease. Medical Journal of Australia, 1992, 157, 298-301.	1.7	321
205	EFFECTS OF 4 WEEKS ENDURANCE TRAINING ON CARDIAC LEFT VENTRICULAR STRUCTURE AND FUNCTION. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 777-783.	1.9	15
206	Effects of Nebivolol on Haemodynamics, Cardiac Dimensions and Function, Cardiovascular Reflexes and Biochemical Measures of Sympathetic Activity in Normal Human Subjects. Drug Investigation, 1991, 3, 51-59.	0.6	4
207	Amplifier function of resistance vessels and the left ventricle in hypertension. Journal of Hypertension, 1991, 9, S31-S41.	0.5	15
208	Neuronal Re-Uptake of Noradrenaline by Sympathetic Nerves in Humans. Clinical Science, 1991, 80, 257-263.	4.3	28
209	Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clinical Autonomic Research, 1991, 1, 187-194.	2.5	61
210	Is adrenaline released by sympathetic nerves in man?. Clinical Autonomic Research, 1991, 1, 103-108.	2.5	29
211	EVIDENCE FOR A ROLE FOR THE CARDIOVASCULAR AMPLIFIERS IN HUMAN PRIMARY HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 37-41.	1.9	1
212	ADRENALINE RELEASE BY THE HUMAN HEART. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 67-70.	1.9	9
213	What is the Dose-Response Relationship between Exercise Training and Blood Pressure?. Annals of Medicine, 1991, 23, 313-318.	3.8	38
214	Evidence of a Selective Increase in Cardiac Sympathetic Activity in Patients with Sustained Ventricular Arrhythmias. New England Journal of Medicine, 1991, 325, 618-624.	27.0	403
215	Effects of Exercise and Other Nonpharmacological Measures on Blood Pressure and Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 1991, 17, S70-S74.	1.9	20
216	Effects of Exercise and Other Nonpharmacological Measures on Blood Pressure and Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 1991, 17, S70???S74.	1.9	5

#	Article	IF	Citations
217	Time-course of the antihypertensive and autonomic effects of regular endurance exercise in human subjects. Journal of Hypertension, 1990, 8, 859-866.	0.5	91
218	Altered venous responses to vasoconstrictor agonists and nerve stimulation in human primary hypertension. Journal of Hypertension, 1990, 8, 1119-1128.	0.5	17
219	Differences in the Neuronal Removal of Circulating Epinephrine and Norepinephrine. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1710-1720.	3.6	43
220	Effect of Endurance Exercise on Cardiac Secretion and Renal Clearance of Atrial Natriuretic Peptide in Normal Humans. Clinical and Experimental Hypertension, 1990, 12, 1223-1235.	0.3	2
221	Initial therapy of primary hypertension. Medical Journal of Australia, 1990, 152, 198-203.	1.7	6
222	Noradrenaline Release and the Pathophysiology of Primary Human Hypertension. American Journal of Hypertension, 1989, 2, 140S-146S.	2.0	112
223	Measurement of overall and cardiac norepinephrine release into plasma during cognitive challenge. Psychoneuroendocrinology, 1989, 14, 477-481.	2.7	99
224	Cardiac Secretion and Renal Clearance of Atrial Natriuretic Peptide in Normal Man: Effect of Salt Restriction. Clinical Science, 1989, 77, 605-610.	4.3	22
225	Cardiovascularâ€risk reduction: initial diuretic therapy compared with calciumâ€antagonist (felodipine) therapy for primary hypertension. Medical Journal of Australia, 1989, 151, 277-279.	1.7	5
226	Release of noradrenaline into the cerebrovascular circulation in patients with primary hypertension. Journal of Hypertension, 1988, 6, S494-496.	0.5	16
227	The Place of Exercise in the Long-Term Treatment of Hypertension. Nephron, 1987, 47, 30-33.	1.8	9
228	Mechanism of Elevated Plasma Noradrenaline in the Course of Essential Hypertension. Journal of Cardiovascular Pharmacology, 1986, 8, S39-S43.	1.9	115
229	Sympathetic tone in congestive heart failure. American Journal of Cardiology, 1985, 56, 912.	1.6	0
230	Redevelopment of Essential Hypertension after Cessation of Long Term Therapy; Preliminary Findings. Clinical and Experimental Hypertension, 1984, 6, 493-505.	0.3	13
231	Plasma noradrenaline kinetics in humans. Journal of the Autonomic Nervous System, 1984, 11, 125-144.	1.9	87
232	Biochemical Quantification of Sympathetic Nervous Activity in Humans Using Radiotracer Methodology. Journal of Cardiovascular Pharmacology, 1982, 4, S152-S157.	1.9	35
233	Radiotracer Methodology for the Simultaneous Estimation of Total, and Renal, Sympathetic Nervous System Activity in Humans. Clinical Science, 1982, 63, 285s-287s.	0.0	36
234	ASSESSMENT OF NEURONAL UPTAKE OF NORADRENALINE IN HUMANS: DEFECTIVE UPTAKE IN SOME PATIENTS WITH ESSENTIAL HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 1980, 7, 535-539.	1.9	12

#	Article	IF	Citations
235	Determination of norepinephrine apparent release rate and clearance in humans. Life Sciences, 1979, 25, 1461-1470.	4.3	328
236	Development and use of a Cardiac Clinical Guideline mobile app in Australia: An acceptability and multimethods study. (Preprint). JMIR Formative Research, 0, , .	1.4	0